• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Endotheliopathy Marked by High von Willebrand Factor (vWF) Antigen in COVID-19 is Associated with Poor Outcome: A Systematic Revi

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2021 Jun 27;S1201-9712(21)00540-3.
doi: 10.1016/j.ijid.2021.06.051. Online ahead of print.
Endotheliopathy Marked by High von Willebrand Factor (vWF) Antigen in COVID-19 is Associated with Poor Outcome: A Systematic Review and Meta-analysis


Arief Wibowo[SUP] 1 [/SUP], Raymond Pranata[SUP] 2 [/SUP], Michael Anthonius Lim[SUP] 3 [/SUP], Mohammad Rizki Akbar[SUP] 4 [/SUP], Januar Wibawa Martha[SUP] 4 [/SUP]



Affiliations

Abstract

Background: In this systematic review and meta-analysis, we aimed to compare the level of von Willebrand Factor (vWF) antigen in patients with poor outcome compared to those without. Additionally, we also explored factors that may affect the difference in terms of vWF antigen between the two groups.
Methods: A comprehensive literature search was performed using the PubMed, Embase, and Scopus databases from inception up until 7 April 2021. The main outcome was poor outcome, which is a composite of mortality and severe COVID-19.
Results: There are 10 studies comprising of 996 patients included in this systematic review and meta-analysis. vWF antigen was higher in patients with poor outcome (standardized mean difference [SMD] 0.84 [0.45, 1.23], p<0.001; I[SUP]2[/SUP]: 87.3, p<0.001). Subgroup analysis on vWF antigen that uses percentage as unit (mean difference 121.6 [53.7, 189.4], p<0.001; I[SUP]2[/SUP]: 92.0, p<0.001). Meta-regression showed that the SMD between poor outcome and good outcome was affected by platelets (coefficient: 0.0061, p=0.001), d-dimer (coefficient: 0.0007, p=0.026), and factor VIII level (coefficient: 0.0057, p=0.031), but not by age (coefficient: -0.0610, p=0.440), gender (coefficient: 0.0135, p=0.698), obesity (coefficient: 0.0282, p=0.666), hypertension (coefficient: 0.0273, p=0.423), diabetes (coefficient: 0.0317, p=0.398), malignancy (coefficient: 0.0487, p=0.608).
Conclusion: This meta-analysis showed that the level of vWF antigen was significantly higher in patients with poor outcome, signaling a marked endotheliopathy. Meta-regression showed that differences became larger as the number of platelets, d-dimer levels, and factor VIII levels increases.

Keywords: Coagulopathy; Coronavirus; Endothelial dysfunction; Mortality; Thrombosis.
 
Back
Top Bottom